BTK inhibitors launched or being developed in cancer have extensive clinical safety and efficacy data already established and that will allow for efficient expansion into autoimmune disease indications, bypassing typical Phase 1a/b activities and moving directly into phase 2 or event phase 2/3 trials. Here, BTK is linked to autoimmune disease.